Menu
Recruiting NCT03886961

The Effect of the Reflux Band™ Upper Esophageal Sphincter (UES) Assist Device on Reflux for Lung Transplant Recipients

No phase Interventional Lung Transplant GERD

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Reflux Band.
Who it may be relevant to
Registry conditions: Lung Transplant, GERD. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

A prospective, open label, study designed to assess the affect of the Reflux Band® UES Assist Device (Reflux Band) on reflux in patients that have undergone lung transplantation.

Interventions

  • Device Reflux Band
    The Reflux Band is to be worn when sleeping by lung transplant patients for 4 weeks starting 8 weeks after transplant.

Primary outcome measures

  • Change in pepsin levels [Time frame: Baseline; Week 4; Week 8]
  • Change in amylase levels [Time frame: Baseline; Week 4; Week 8]

Eligibility criteria

Inclusion criteria

  • Clinically stable lung transplant patients(single lung, double lung, or re-transplant) as defined by stable FEV1 over the prior two visits
  • 13 Abnormal pH impedence or esophagram or documented gastric reflux at pre-transplant evaluation
  • Patient must be willing and able to provide informed consent
  • Understands the clinical study requirements and is able to comply with follow-up schedule

Exclusion criteria

  • Currently being treated with another investigational medical device and/or drug
  • Currently receiving treatment for sleep apnea with continuous positive airway pressure (CPAP)
  • Previous head or neck surgery / radiation
  • Carotid artery disease, thyroid disease, or history of cerebral vascular disease
  • Nasopharyngeal cancer
  • Suspected esophageal cancer

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Prevention

Study locations

United States · 1 center
  • UF Health at the University of Florida — Gainesville

Identifiers

NCT: NCT03886961 · IRB201900469 -A

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗